NEW YORK (TheStreet) -- Shares of Diplomat Pharmacy (DPLO) were plunging 37.71% to $13.94 on heavy trading volume Thursday morning after reporting lower-than-expected results for the third quarter and cutting its outlook for the full year.
After yesterday's market close, the Flint, MI-based independent specialty pharmacy reported adjusted earnings of 21 cents per share, missing analysts' estimates of 24 cents per share. Revenue rose 25% year-over-year to $1.18 billion but fell short of analysts' projections of $1.26 billion.
Diplomat Pharmacy blamed the downbeat results on weakness in its hepatitis C business as well as direct-and-indirect renumeration fees.
For the full year, Diplomat Pharmacy now expects to report adjusted earnings between 83 cents and 87 cents per share on revenue between $4.4 billion and $4.6 billion. The company had previously anticipated adjusted earnings between 90 cents and 95 cents per share on revenue between $4.5 billion and $4.9 billion.
Analysts surveyed by FactSet are looking for adjusted earnings of 87 cents per share on $4.59 billion in revenue for the year.
Leerink subsequently downgraded the stock to "market perform" from "outperform" and slashed its price target to $18 from $35.
Diplomat Pharmacy is facing "significant headwinds" from direct-and-indirect renumeration fees, and there is risk to negative revisions to inflation assumptions in 2017, the firm said.
About 10.43 million shares of Diplomat Pharmacy have been traded so far today, well above the company's average trading volume of roughly 918,764 shares a day.
Separately, TheStreet Ratings team rates the stock as a "hold" with a ratings score of C-.
Diplomat's strengths such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income are countered by weaknesses including a generally disappointing performance in the stock itself and poor profit margins.
You can view the full analysis from the report here: DPLO
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.